Report : Europe Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
At 13.6% CAGR, Europe Vaccine Adjuvants Market is Projected to be Worth US$ 2,051.05 Million by 2030, says Business Market Insights
According to Business Market Insights’ research, the Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030, registering a CAGR of 13.6% from 2022 to 2030. Advancements in biotechnology and immunology and rising number of infectious disease outbreaks and pandemic are among the critical factors attributed to drive the Europe vaccine adjuvants market growth.
The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.
On the contrary, product recalls and adverse effects hamper the growth of Europe vaccine adjuvants market.
Based adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held 39.0% share of Europe vaccine adjuvants market share in 2022, amassing US$ 288.43 million. It is projected to garner US$ 761.27 million by 2030 to register 12.9% CAGR during 2022–2030.
By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held 62.8% share of Europe vaccine adjuvants market in 2022, amassing US$ 472.33 million. It is anticipated to garner US$ 1,338.00 million by 2030 to expand at 13.9% CAGR during 2022–2030.
By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany segment held 25.6% share of Europe vaccine adjuvants market in 2022, amassing US$ 189.29 million. It is anticipated to garner US$ 512.81 million by 2030 to expand at 13.3% CAGR during 2022–2030
Key players operating in the Europe vaccine adjuvants market are Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc, among others.
- October, 2023; SPI Pharma Inc and Q-Vant Biosciences Inc announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in expanding Q-Vant’s proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com